Bovine papillomavirus 4 (BPV-4) is a mucosal epitheliotropic papillomavirus. It encodes a transcriptional regulator, E2, which acts on the BPV-4 transcriptional control region (the long control region or LCR) to regulate transcription. The distribution of E2 binding sites within the LCR of BPV-4 is identical to that of the human papillomaviruses HPV-16 and HPV-18, indicating that the mechanism of transcriptional control by E2 of mucosal epitheliotropic papillomaviruses is conserved. In this study it has been shown that E2 activates transcription through the BPV-4 LCR promoter in primary bovine palate keratinocytes but not in primary bovine palate fibroblasts. The epithelial specific transcriptional activation of the BPV-4 LCR by E2 is promoter-specific because following binding to
Introduction
Like HPV-16 and HPV-18, BPV-4 is a mucosal epitheliotropic virus. It induces papillomas in the upper alimentary canal of cattle which can progress to carcinoma in cattle feeding on bracken fern (Campo et al., 1994) . One of the restrictions of these viruses to mucosal epithelium occurs at the transcriptional level. Following infection of epithelial cells, cellular factors activate transcription from the long control region (LCR), resulting in the expression of the transforming genes of these viruses (Hoppe-Seyler & Butz, 1994) . The major oncoproteins of BPV-4 are the products of the E8 and E7 ORFs located immediately downstream of the BPV-4 LCR.
Transcription from the LCR is regulated by E2 as well as by cellular factors. E2 is a transcription factor which binds a 12 bp palindromic DNA recognition sequence as a dimer (for a review, see Ham et al., 1991 a) . The dimerization and DNA binding region of E2 is in the carboxy-terminal region of the Author for correspondence : Iain M. Morgan. Fax j44 141 942 6521. e-mail imm2x!udcf.gla.ac.uk the BPV-4 LCR placed in an enhancer mode, E2 can activate transcription from heterologous promoters, such as SV40, in both keratinocytes and fibroblasts. Chimaeric VP16-E2 molecules suggest that the epithelial specific transcriptional activation of the BPV-4 LCR promoter is mediated by the E2 transactivation domain. Although low to intermediate levels of E2 can activate transcription from the BPV-4 LCR promoter, high levels of E2 result in down-regulation of transcription from this promoter in keratinocytes. Mutation of E2 binding site 1 (BS1), which is 3 bp upstream from the TATA box, abrogates down-regulation of transcription by high levels of E2. The results present a model system for studying transcriptional regulation of mucosal epitheliotropic papillomavirus LCRs by E2.
protein and an acidic transactivation domain resides in the amino-terminal 200 amino acids (Giri & Yaniv, 1988 a) . The transactivation and DNA binding domains are separated by a variable hinge region. All E2 proteins have this tripartite structure (Giri & Yaniv, 1988 b) and regulate transcription from a variety of papillomavirus promoters. BPV-1 also expresses truncated versions of E2 which act as transcriptional repressors (McBride et al., 1988) . E2 can activate transcription from heterologous promoters in a variety of cell types (Cripe et al., 1987 ; Romanczuk et al., 1990 ; Thierry & Yaniv, 1987) and like other transcription factors that function in mammalian cells, E2 can activate transcription in yeast (Morrissey et al., 1989 ; Stanway et al., 1989) .
As well as regulating transcription, E2 can interact with the E1 protein to assist in the replication of the virus (Demeret et al., 1995 ; Sedman & Stenlund, 1995 ; Ustav & Stenlund 1991 ; Yang et al., 1991) . E2 facilitates efficient binding of the E1 protein, which is the major replication factor of the papillomaviruses, to its target DNA sequence (Seo et al., 1993) . The E1 DNA binding site is always juxtaposed with an E2 DNA binding site. The transcription and replication functions of the (Jackson & Campo, 1995 ; Romanczuk et al., 1990) . There are 3 bp between the TATA box and BS1, and between BS1 and BS2 in each of these promoters as shown in detail in the lower part of the figure. In HPV-16 there is 81 bp between sites BS2 and BS3 while in BPV-4 there are 77 bp between these sites. There are 409 bp and 390 bp between BS1 and BS2 in HPV-16 and BPV-4, respectively. Therefore, the distribution of E2 sites in the LCRs of mucosal epitheliotropic papillomaviruses shows remarkable conservation throughout evolution. The nomenclature of the sites in the BPV-4 LCR has been altered from that published previously (Jackson & Campo 1995) thus : BS4 l E2(1) ; BS3 l E2(2) ; BS2 l dE2 ; BS1 l E2(3).
E2 protein can be separated by point mutations within the amino-terminal 200 amino acids (Ferguson & Botchan, 1996 ; Grossel et al., 1996 ; Sakai et al., 1996 ; Winokur & McBride, 1992) .
In addition to enhancing expression of transforming genes, activation of transcription from the LCR results in expression of E1 and E2. As a consequence regulation of transcription from the papillomavirus LCR promoter by E2 controls not only the expression of the viral oncogenes but also expression of E1 and E2. This regulation of transcription by E2 from the LCR promoter is therefore essential to the virus life cycle (Storey et al., 1992) .
The distribution of E2 sites within the LCR of BPV-4 is essentially identical to that of other mucosal epitheliotropic papillomaviruses such as HPV-16 and 18 (see Fig. 1 ). Immediately upstream from the TATA box there are two DNA binding sites for E2 that are separated from the TATA box and from each other by 3 or 4 bp. There are two sites further upstream, one juxtaposed with the E1 DNA binding site and presumed to be involved in regulating replication of the viral DNA, and one a further 300 or 400 bp upstream. The conservation of these sites through evolution demonstrates that the mechanism of transcriptional regulation of the LCRs by E2 is conserved.
Overexpression of E2 results in repression of transcription from the HPV-16 and 18 promoters in a variety of established epithelial cell lines (Romanczuk et al., 1990 ; Tan et al., 1992 Tan et al., , 1994 Thierry & Yaniv, 1987) . This repression can be alleviated by mutation of the TATA-box-proximal E2 site (Romanczuk et al., 1990 ; Steger & Corbach, 1997) . E2 can interact with TATA box binding protein (TBP) and it is hypothesized that the repression of the HPV-16 and 18 promoters by E2 is mediated through interaction with TBP, resulting in a down-regulation of transcriptional initiation (Steger et al., 1995 ; Tan et al., 1994) . In contrast to the HPV-16 and 18 promoters, BPV-4 E2 can upregulate transcription from the BPV-4 promoter in its target cell type, primary palate keratinocytes (Jackson & Campo, 1995) . We further exploited this system by examining the tissue specificity of the response to E2 and determining the role of the TATA-box-proximal E2 site (BS1) in transcriptional down-regulation by elevated levels of E2. The results demonstrate a tissue-specific up-regulation of transcription from the BPV-4 LCR promoter by E2 that is specific to this promoter and possibly mediated by the E2 transactivation domain. They also show that E2 BS1 is responsible for down-regulating the levels of transcription from the BPV-4 promoter at elevated levels of E2. The BPV-4 LCR presents a model to study the mechanism of E2 transcriptional regulation of mucosal epitheliotropic papillomaviruses and the tissue specificity of this regulation.
Methods
Plasmids. The LCR of BPV-4 was cloned into the BglII site of the luciferase reporter plasmid pGL3 (Promega). The LCR was cloned as a BamHI fragment removed from a p0luc vector described previously (Jackson & Campo, 1995) . The resulting pGL3 vector had at least an order of magnitude higher activity than the p0luc vector. The mutant LCR fragments were also subcloned into pGL3 and the resulting clones sequenced to confirm the presence of the correct mutation in each construct. The E2 expression vectors pBG331, pBG331 BPV-4 E2 and pBG331 BPV-1 E2 have been described previously (Jackson & Campo, 1995) . To insert the BPV-4 LCR in an enhancer mode upstream from the SV40 promoter, the same BamHI fragment used to construct the pGL3 vector was inserted into the BglII site of pGL3PRO (Promega). The SV40 promoter drives expression of the luciferase gene. pCGE2 and pCGVP16-E2 were kind gifts from Mart Ustav (Estonian Biocentre, Tartu, Estonia).
Cell culture. Primary bovine palate keratinocytes (PalKs) were prepared from foetal biopsies as described for human cervical keratinocytes (Cuthill et al., 1993) . They were cultured on irradiated Swiss 3T3 feeders under the conditions described by Jackson & Campo (1995) . The Swiss 3T3 feeders were grown in 1i Dulbecco's Modified Eagle's Medium (DMEM) with 10 % foetal calf serum and irradiated with 60 Gy prior to use. Primary bovine palate fibroblasts (PalFs) were prepared as described by Jaggar et al. (1990) from the same palate biopsy used to prepare PalKs and cultured in 1i DMEM with 10 % foetal calf serum. At least two different sources of these primary cell types were used in the experiments described.
Transfection. PalK cells were transfected using the Polybrene-DMSO technique described by Jiang et al. (1991) . Briefly, 5i10& cells were seeded on a 60 mm tissue culture dish without feeders. The Epithelial specific transcription by E2 Epithelial specific transcription by E2 following day the medium was replaced with medium containing 10 µg\ml polybrene and the DNA added. After 6 h the medium was removed and a 35 % DMSO solution added to the cells for 3 min. Following this incubation the cells were washed twice with PBS and then re-fed with normal medium. The cells were harvested 44-48 h later. PalF cells were transfected using a standard calcium phosphate precipitation technique. Briefly, cells were plated out at 2i10& per 60 mm tissue culture dish. The following day a calcium phosphate precipitate containing the DNA was added to the cells overnight. The next morning the cells were washed twice with PBS and re-fed with normal medium. The cells were harvested 28-32 h later.
Transcription assay. PalK cells were lysed directly on the tissue culture plates. The medium was removed and the cells washed twice with PBS. Reporter Lysis Buffer (Promega) (300 µl) was added to the plate and left for 10 min. The cell lysate was then scraped from the dish and placed in a 1n5 ml centrifuge tube. The lysate was cleared by centrifugation of the sample for 10 min and removal of the supernatant to a fresh tube. The supernatant (80 µl) was then assayed for luciferase activity using the Luciferase Assay System (Promega) with a BioOrbit 1251 luminometer. To standardize for cell number, the protein concentration was determined. PalF cells were removed from the tissue culture plate using TEN buffer (0n04 M Tris-HCl, pH 7n4, 1 mM EDTA, 0n15 M NaCl) prior to lysing the cells. The cells were resuspended in 100 µl Reporter Lysis Buffer and 50 µl of this suspension was used in the Luciferase assays as described for the PalK extracts. pGL3CONT (containing the SV40 promoter and enhancer driving expression of the luciferase gene) was transfected in parallel into PalF cells to confirm efficient transfection. This construct demonstrates high levels of transcriptional activity in fibroblasts. All transfections were repeated at least three times in duplicate.
Results

E2 activates transcription from the BPV-4 LCR in an epithelial specific manner
BPV-4 E2 can enhance transcription from the BPV-4 LCR promoter in keratinocytes. To determine if this enhancement is cell-type-specific, PalKs and PalFs were prepared from a palate chip of a bovine foetus. To increase sensitivity of the transcription assays, the BPV-4 LCR was sub-cloned from the p0luc vector into pGL3. In PalKs this resulted in at least an order of magnitude increase in the levels of the reporter gene product, luciferase. Such an increase is particularly crucial to the experiments performed in PalFs. In PalFs the LCR has a dramatically reduced transcriptional activity when compared with PalKs (data not shown) and without sub-cloning of the LCR into pGL3, the level of transcription from the LCR promoter in PalFs is undetectable. The ability of BPV-4 E2 to activate transcription from the LCR promoter was determined using these new reporter vectors and the results are shown in Fig. 2 . In Fig. 2 (a) it is clear that BPV-4 E2 activated transcription from the BPV-4 LCR promoter as described previously (Jackson & Campo, 1995) . This activation was three-to fourfold at low and intermediate levels of E2 while high levels of E2 resulted in down-regulation of transcriptional activation. In contrast, in PalFs E2 failed to activate transcription from the LCR promoter at any E2 levels assayed (Fig.  2 b) . BPV-4 E2 can also activate transcription from the LCR promoter in human epithelial cells but failed to do so in murine fibroblasts (data not shown), indicating an epithelial specific transcriptional activation from the LCR promoter by BPV-4 E2.
BPV-4 E2 activates transcription from a heterologous promoter in a cell-type-independent manner
To investigate whether the failure of E2 to activate transcription in fibroblasts was promoter-specific or a property of BPV-4 E2, the BPV-4 LCR was cloned in an enhancer mode upstream of the SV40 promoter to give pGL3PRO LCR. In the absence of E2, the LCR enhanced transcription from the SV40 promoter in epithelial cells but not in fibroblasts (Fig. 3 a) . However, BPV-4 E2 could up-regulate transcription from the SV40 promoter via the BPV-4 LCR in both PalKs and PalFs (Fig. 3 b) . In contrast to the results obtained with the LCR promoter, increasing levels of BPV-4 E2 enhanced transcriptional activation from the SV40 promoter 25-fold in PalKs and 10-fold in PalFs at the highest levels of E2. BPV-4 E2 had no effect on the SV40 promoter alone (data not shown). These results demonstrate that BPV-4 E2 is competent to activate transcription in PalFs and that the failure to activate the LCR promoter in fibroblasts (Fig. 2 b) is a promoter-specific effect. 
The TATA-box-proximal E2 binding site mediates transcriptional down-regulation at high levels of E2
In Fig. 2 (a) it is clear that overexpression of E2 results in the down-regulation of transcriptional activation from the BPV-4 LCR promoter. Such down-regulation is typical of a squelching mechanism in which the overexpression of E2 results in the titration of a factor required for transcriptional activation. However, it is also possible that this down-regulation occurs through E2 binding to the TATA-box-proximal E2 site, interfering with TBP binding and, therefore, transcriptional initiation, as reported for BPV-1 E2 (Steger et al., 1995) . Moreover, overexpression of BPV-4 E2 does not result in a reduction of the ability of E2 to activate transcription from the SV40 promoter. Indeed, increased levels of E2 resulted in increased transcriptional activation from the SV40 promoter (Fig. 3 b) . To look at the contribution that the E2 sites proximal to the TATA box in the BPV-4 LCR make in down-regulating transcription by high levels of E2, they were mutated so that they could no longer bind E2 (Fig. 4 a) (Jackson & Campo, 1995) . The mutant LCRs were then transfected into PalKs and their transcriptional response to increasing amounts of E2 determined. The results are shown in Fig. 4 (b) . The wild-type LCR showed the familiar transcriptional response ; activation by E2 at low levels followed by down-regulation at high levels. Mutation of E2 BS1 abrogated this down-regulation ; the LCR was six to seven times more transcriptionally active at high levels of E2 when BS1 is mutated. This demonstrates that down-regulation of transcription is not the result of a squelching mechanism but more likely related to interference with TBP binding. Mutation of BS2 made little difference to the response of the LCR to BPV-4 E2.
Epithelial specific transcriptional activation of the LCR promoter by E2 may be mediated by the transactivation domain
There are several possible reasons why E2 fails to activate transcription from the LCR promoter in fibroblasts. First, the low level of transcription from this promoter (data not shown) may make it unresponsive to transcriptional up-regulation by E2. Second, E2 may fail to bind its target sequences due to blocking of these sites by cellular factors. Third, the transactivation domain of E2 may fail to activate transcription from this promoter in fibroblasts. To determine which of these possibilities may be correct we employed a chimaeric molecule from the VP16 transactivation domain and the BPV-1 E2 DNA binding domain. Wild-type BPV-1 E2 was also used. BPV-1 E2 Table 1. interacts with TBP (Steger et al., 1995 ; Tan et al., 1994) and has an enhanced binding capacity for BS1 of mucosal epitheliotropic papillomaviruses when compared with E2s from these viruses. This enhanced binding to BS1 can result in repression of the wild-type LCRs by BPV-1 E2 (Romanczuk et al., 1990 ; Steger & Corbach, 1997) . We also analysed the ability of VP16-E2 and wild-type BPV-1 E2 to activate transcription from LCR-BS1. The results of these experiments are shown graphically in Fig. 5 and numerically in Table 1 . BPV-1 E2 activated transcription from the LCR at low levels but failed to do so at intermediate levels. This difference between BPV-1 E2 and BPV-4 E2 is presumably due to enhanced binding of BPV-1 E2 to BS1. BPV-1 E2 efficiently activated transcription from LCR-BS1 (Fig. 5 a) . In PalFs, BPV-1 E2 failed to activate transcription and indeed repressed transcription, again probably due to binding to BS1 (Fig. 5 b) . Removal of BS1 also failed to allow BPV-1 E2 to activate transcription in fibroblasts (Fig.  5 b) and BPV-4 E2 failed to activate the BS1 mutant in fibroblasts (data not shown). This demonstrates that the inability of E2 to activate transcription from the LCR in fibroblasts is not due to enhanced binding of E2 to BS1. The overall pattern of transcriptional regulation of the LCR by BPV-1 E2 is similar to that observed with BPV-4 E2 (see Figs  2 and 4) . VP16-E2 can activate transcription from LCR and from LCR-BS1 in both keratinocytes and fibroblasts. The levels The numerical values shown are represented graphically in Fig. 5 . The ratio column relates to the ratio of E2 expression vector to reporter. For details, see the legend to Fig. 5 .
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of transcriptional activation were greater than those obtained for BPV-1 E2 or BPV-4 E2 in keratinocytes and were very similar in fibroblasts and keratinocytes. At elevated levels of VP16-E2 there was a down-regulation of transcription, even with the BS1 mutant, possibly as a result of squelching. These results suggest that the epithelial specific activation by E2 is mediated through the transcriptional activation domain.
Discussion
E2 is essential to the virus life cycle (Storey et al., 1992) and is involved in regulating viral transcription (for a review, see Thierry, 1996) and replication (Demeret et al., 1995 ; Lu et al., 1993 ; Sverdrup & Khan, 1994 ; Yang et al., 1991) . The mechanism by which E2 regulates transcription from the LCRs of mucosal epitheliotropic papillomaviruses is highly conserved as implied by the conservation of the distribution of binding sites for this transcriptional regulator within the LCRs of these viruses (see Fig. 1 ). Here we have suggested a mechanism by which E2 regulates transcription from the LCR promoter involving TBP displacement resulting in downregulation of transcription at elevated levels of E2. We have also demonstrated tissue-specific transcriptional activation of the BPV-4 LCR promoter by BPV-4 E2 and suggested that this tissue specificity is mediated by the transcriptional activation domain. Overall the results support a mechanism in which E2 cell-type-specific transcriptional regulation of epitheliotropic papillomavirus promoters results in a regulated fluctuation in the expression levels of the transforming genes and of the genes that regulate the virus life cycle. LCR promoter as they do from human epitheliotropic papillomavirus promoters (Hoppe-Seyler & Butz, 1994) . Following expression of low levels of E2 there is up-regulation of transcription from the BPV-4 LCR promoter, probably via sites BS4 and BS3. The individual contribution these sites make to transcriptional up-regulation by E2 from the BPV-4 promoter is currently under investigation. This up-regulation of transcription could be mediated by direct interaction of E2 with TBP, or an associated factor, or by a transcriptional adapter protein or interaction with another DNA binding protein.
Elevated levels of E2 result in down-regulation of transcription from the BPV-4 LCR promoter. This down-regulation is mediated by E2 interaction with BS1 and interference with TBP-TATA box interaction and, therefore, transcriptional initiation. E2 can interact directly with TBP (Ham et al., 1994 ; Steger et al., 1995 ; Tan et al., 1994) . Several pieces of information support this as a possible mechanism. First, the results here demonstrate that mutation of BS1 abrogates down-regulation of transcription by elevated levels of E2 (Fig.  4) . Mutation of BS1 in the context of HPV LCRs results in abrogation of transcriptional repression by E2 (Romanczuk et al., 1990 ; Steger & Corbach, 1997) . Second, HPV-16 E2 has a lower affinity for HPV-16 LCR BS1 than for other E2 sites (Steger & Corbach, 1997) , suggesting that this site is likely to be the last site occupied by E2 and may require overexpression of the E2 protein to do so. Also, in the BPV-4 LCR, E2 dissociates more quickly from BS1 and BS2 than from the upstream E2 sites, suggesting that elevated levels of E2 are required to occupy these sites (Jackson & Campo, 1995) . Third, BPV-1 E2 has an enhanced affinity for BS1 in the HPV-16 LCR when compared with HPV-16 E2 (Steger & Corbach, 1997) which would explain the enhanced down-regulation of transcription by BPV-1 E2. The results obtained here with BPV-1 E2 (Fig. 5) suggest that this is also the case with the BPV-4 LCR. E2 can bind co-operatively to DNA at adjacent sites (Monini et al., 1991 (Monini et al., , 1993 Tan et al., 1994) and BS2 may facilitate or enhance the ability of E2 to bind to BS1 and therefore be involved in mediating repression\down-regulation through BS1.
Tissue-specific transcriptional activation of the BPV-4 LCR by E2
BPV-4 E2 can activate transcription of the BPV-4 LCR in the BPV-4 target cell type, PalKs (Fig. 2 a) . This transcriptional activation by E2 is specific to keratinocytes as E2 fails to activate transcription from this promoter in PalFs (Fig. 2 b) . This failure to activate transcription is particular to the LCR promoter as E2 could activate transcription from heterologous promoters such as SV40 (Fig. 3) and tk (data not shown) in both cell types. Such activation of heterologous promoters via upstream E2 DNA binding sites in fibroblast cells is common to other mucosal epitheliotropic papillomavirus E2 proteins and LCRs (Bouvard et al., 1994 ; Romanczuk et al., 1990 ; Thierry & Yaniv, 1987) . Previous studies have failed to present a coherent story as to whether E2 can activate transcription from HPV LCR promoters. Only one report has shown a convincing E2 activation of such a promoter in primary human keratinocytes (Bouvard et al., 1994) . The reason for the failure to consistently observe transcriptional activation of LCRs by E2 proteins could be due to several reasons. First, from our studies and others it is clear that the type and levels of E2 expressed in the cells are crucial to whether activation by E2 is observed. These levels may vary widely with the use of different E2 expression vectors, resulting in a failure to activate transcription by E2. In several studies on these promoters BPV-1 E2 was used and there is clearly a difference in the function of the different E2 proteins. Second, the cell type employed in these transcription studies may also play a crucial role as to whether E2 can activate LCR promoters. In transformed epithelial lines such as HeLa (and in many tumour samples) the HPV-18 genome (or other HPV types) has integrated into the cellular genome, resulting in a loss of E2 function (Baker et al., 1987 ; Sang & Barbosa, 1992 ; Schwarz et al., 1985) . It is hypothesized that this integration favours elevated levels of E6 and E7 expression, resulting in an enhanced transformed phenotype. In such a model it is assumed that E2 is functioning by repressing transcription from the LCR promoter. Therefore, studies determining the ability of E2 to activate transcription of the HPV-18 LCR could result in a failure to see such activation in these transformed cell types. Perhaps activation of the LCR by E2 is required at early points in viral infection for propagation of the virus and for initial expression of the viral oncogenes. In a neoplastic state E2 may no longer be required for such a function and for disease progression it is perhaps necessary to knock out E2 function by insertional inactivation. It may be significant that our present studies and those of others who report transcriptional activation of mucosal epitheliotropic papillomavirus LCRs by E2 have been carried out in primary cells (Bouvard et al., 1994 ; Jackson & Campo, 1995) .
The tissue specificity of E2 function on the viral LCR could be another level of restriction to the target cell type of infection and transformation by mucosal epitheliotropic papillomaviruses. This tissue-specific transcriptional activation by E2 is not extended to other promoters such as SV40 or tk, raising the possibility that there is a specific cellular protein with which E2 interacts to restrict transcriptional activation of the LCR to epithelial cells. This interaction could be mediated by the transactivation domain of E2 as chimaeric VP16-E2 molecules can activate transcription from the LCR promoter in a cell-type-independent manner (Fig. 5 ). There are several possibilities for the nature of such an interacting protein. First, there may be a transcriptional adapter protein present in epithelial cells that assists in the activation of transcription by E2. Such an adapter may interact at the TATA box complex itself or act as a bridge between the TATA box complex and E2. Second, there may be a protein that binds to the LCR in FAG epithelial cells and interacts with E2 to assist in transcriptional activation. E2 proteins can interact with other transcription factors both directly and by interfering with DNA binding (Demeret et al., 1994 ; Dong et al., 1994 ; Ham et al., 1991 b ; Li et al., 1991 ; Sandler et al., 1996 ; Stenlund & Botchan, 1990 ; Tan et al., 1992) to regulate transcription from adjacent promoters. Third, an enzyme, such as a kinase, may modify the E2 protein in an epithelial specific manner, resulting in enhanced interactions with cellular proteins. Fourth, it is equally possible that there is a repressor protein present in fibroblasts that inhibits the ability of E2 to activate transcription. All of the options discussed are currently under investigation. If an E2 interacting protein could be identified that was responsible for mediating epithelial specific transcriptional activation, such a protein would clearly represent an ideal target for interrupting the virus life cycle.
